Abstract
Incorporation of green chemistry techniques and methodologies into nanotechnology is of great interest which has gained much attention over the past decade...
Highlights
Atomoxetine HClAtomoxetine is the first non-stimulant drug approved for the treatment of an attention-deficit hyperactivity disorder (ADHD)
The present work described the development of a high-performance liquid chromatographic (HPLC) method for determination atomoxetine & fluoxetine in their pharmaceutical dosage forms Strattera® & Prozac®
The proposed HPLC method can be used for the quality control of formulated products containing atomoxetine or fluoxetine or both
Summary
Atomoxetine HClAtomoxetine is the first non-stimulant drug approved for the treatment of an attention-deficit hyperactivity disorder (ADHD). The present work described the development of a high-performance liquid chromatographic (HPLC) method for determination atomoxetine & fluoxetine in their pharmaceutical dosage forms Strattera® & Prozac®. The developed method was linear over the concentration range of 1-16 g/ml (r = 0.99999) with a limit of detection 0.028 and 0.065 g/ml for atomoxetine & fluoxetine respectively and a limit of quantitation 0.085 and 0.198 g/ml for atomoxetine & fluoxetine respectively.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Biomedical Journal of Scientific & Technical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
